Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eli Lilly and Company
Pediatric Brain Tumor Consortium
Washington University School of Medicine
Stanford University
Milton S. Hershey Medical Center
Columbia University
Mayo Clinic
Istari Oncology, Inc.
Hackensack Meridian Health
Mayo Clinic
Washington University School of Medicine
BioMimetix JV, LLC
St. Joseph's Hospital and Medical Center, Phoenix
Washington University School of Medicine
Thomas Jefferson University
University of Pittsburgh
National Cancer Institute (NCI)
University of California, San Francisco
Children's Oncology Group
University of Florida
M.D. Anderson Cancer Center
Dartmouth-Hitchcock Medical Center
National Cancer Institute (NCI)
Imperial College London
Massachusetts General Hospital
Dana-Farber Cancer Institute
National Institutes of Health Clinical Center (CC)
Virginia Commonwealth University
Radiation Therapy Oncology Group
Basilea Pharmaceutica
Pediatric Brain Tumor Consortium
Celgene
Istari Oncology, Inc.
Memorial Sloan Kettering Cancer Center
Candel Therapeutics, Inc.
Lumos Pharma
Exelixis
Novartis
Southern Illinois University
National Institutes of Health Clinical Center (CC)
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc.
H. Lee Moffitt Cancer Center and Research Institute
Istari Oncology, Inc.
Eisai Inc.
Novartis
Duke University